Kathinka Schmidt Slørdahl, Aina Balto, Marianne Grønlie Guren, Arne Wibe, Hartwig Kørner, Stig Norderval, Ylva Maria Gjelsvik, Tor Åge Myklebust, Inger Kristin Larsen
{"title":"直肠癌治疗后的患者报告结果--一项前瞻性全国研究。","authors":"Kathinka Schmidt Slørdahl, Aina Balto, Marianne Grønlie Guren, Arne Wibe, Hartwig Kørner, Stig Norderval, Ylva Maria Gjelsvik, Tor Åge Myklebust, Inger Kristin Larsen","doi":"10.1111/codi.17231","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>While modern treatment has improved rectal cancer (RC) survival, it can cause late side effects that impact health-related quality of life (HRQoL). The aim of this study was to evaluate HRQoL and late effects 1 year after diagnosis in patients who underwent major resection for Stage I-III RC.</p><p><strong>Method: </strong>All patients with RC registered in the Cancer Registry of Norway between 1 January 2019 and 31 December 2020, aged ≥ 18 years, and a control group without colorectal cancer were invited to participate in the study by answering a questionnaire on HRQoL and late effects. Functional domains and symptoms were compared in different patient groups and between patients and controls.</p><p><strong>Results: </strong>There were 558 patients and 1693 controls eligible for analysis. Response rates were 41% for patients and 23% for controls. Some differences in HRQoL were observed between treatment modalities. Major low anterior resection syndrome (LARS) was prevalent in 60.8% of patients, and was associated with lower functional and higher symptom scores compared with patients with no/minor LARS. Patients with major chronic pain [n = 86 (15.4%)] had significantly lower scores for most of the functional items and higher symptom scores than patients with no/minor chronic pain. Patients had some lower functional scores and several higher symptoms score compared with controls.</p><p><strong>Conclusion: </strong>Patients who suffered from major LARS or major chronic pain had significantly impaired functions and more symptoms beyond change in bowel function and pain, respectively. Identification and treatment of these patient may hopefully be beneficial for their HRQoL.</p>","PeriodicalId":10512,"journal":{"name":"Colorectal Disease","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patient-reported outcomes after treatment for rectal cancer-A prospective nationwide study.\",\"authors\":\"Kathinka Schmidt Slørdahl, Aina Balto, Marianne Grønlie Guren, Arne Wibe, Hartwig Kørner, Stig Norderval, Ylva Maria Gjelsvik, Tor Åge Myklebust, Inger Kristin Larsen\",\"doi\":\"10.1111/codi.17231\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>While modern treatment has improved rectal cancer (RC) survival, it can cause late side effects that impact health-related quality of life (HRQoL). The aim of this study was to evaluate HRQoL and late effects 1 year after diagnosis in patients who underwent major resection for Stage I-III RC.</p><p><strong>Method: </strong>All patients with RC registered in the Cancer Registry of Norway between 1 January 2019 and 31 December 2020, aged ≥ 18 years, and a control group without colorectal cancer were invited to participate in the study by answering a questionnaire on HRQoL and late effects. Functional domains and symptoms were compared in different patient groups and between patients and controls.</p><p><strong>Results: </strong>There were 558 patients and 1693 controls eligible for analysis. Response rates were 41% for patients and 23% for controls. Some differences in HRQoL were observed between treatment modalities. Major low anterior resection syndrome (LARS) was prevalent in 60.8% of patients, and was associated with lower functional and higher symptom scores compared with patients with no/minor LARS. Patients with major chronic pain [n = 86 (15.4%)] had significantly lower scores for most of the functional items and higher symptom scores than patients with no/minor chronic pain. Patients had some lower functional scores and several higher symptoms score compared with controls.</p><p><strong>Conclusion: </strong>Patients who suffered from major LARS or major chronic pain had significantly impaired functions and more symptoms beyond change in bowel function and pain, respectively. Identification and treatment of these patient may hopefully be beneficial for their HRQoL.</p>\",\"PeriodicalId\":10512,\"journal\":{\"name\":\"Colorectal Disease\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Colorectal Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/codi.17231\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colorectal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/codi.17231","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:虽然现代治疗提高了直肠癌(RC)的生存率,但它可能会导致晚期副作用,影响健康相关生活质量(HRQoL)。本研究旨在评估因I-III期直肠癌接受大部切除术的患者确诊1年后的HRQoL和晚期副作用:方法:邀请2019年1月1日至2020年12月31日期间在挪威癌症登记处登记的所有年龄≥18岁的RC患者以及未患结肠直肠癌的对照组患者参与研究,回答有关HRQoL和后期影响的问卷。对不同患者组、患者与对照组的功能领域和症状进行了比较:符合分析条件的患者有 558 人,对照组有 1693 人。患者的回复率为 41%,对照组为 23%。在不同治疗方式之间,观察到了一些 HRQoL 方面的差异。60.8%的患者患有严重低位前切除综合征(LARS),与无/轻度 LARS 患者相比,其功能评分较低,症状评分较高。与无/轻度慢性疼痛患者相比,重度慢性疼痛患者[n = 86 (15.4%)]的大部分功能项目评分明显较低,症状评分较高。与对照组相比,患者的部分功能评分较低,而症状评分较高:结论:重度 LARS 或重度慢性疼痛患者的功能明显受损,除肠道功能和疼痛变化外,还伴有更多症状。对这些患者进行识别和治疗,有望改善他们的 HRQoL。
Patient-reported outcomes after treatment for rectal cancer-A prospective nationwide study.
Aim: While modern treatment has improved rectal cancer (RC) survival, it can cause late side effects that impact health-related quality of life (HRQoL). The aim of this study was to evaluate HRQoL and late effects 1 year after diagnosis in patients who underwent major resection for Stage I-III RC.
Method: All patients with RC registered in the Cancer Registry of Norway between 1 January 2019 and 31 December 2020, aged ≥ 18 years, and a control group without colorectal cancer were invited to participate in the study by answering a questionnaire on HRQoL and late effects. Functional domains and symptoms were compared in different patient groups and between patients and controls.
Results: There were 558 patients and 1693 controls eligible for analysis. Response rates were 41% for patients and 23% for controls. Some differences in HRQoL were observed between treatment modalities. Major low anterior resection syndrome (LARS) was prevalent in 60.8% of patients, and was associated with lower functional and higher symptom scores compared with patients with no/minor LARS. Patients with major chronic pain [n = 86 (15.4%)] had significantly lower scores for most of the functional items and higher symptom scores than patients with no/minor chronic pain. Patients had some lower functional scores and several higher symptoms score compared with controls.
Conclusion: Patients who suffered from major LARS or major chronic pain had significantly impaired functions and more symptoms beyond change in bowel function and pain, respectively. Identification and treatment of these patient may hopefully be beneficial for their HRQoL.
期刊介绍:
Diseases of the colon and rectum are common and offer a number of exciting challenges. Clinical, diagnostic and basic science research is expanding rapidly. There is increasing demand from purchasers of health care and patients for clinicians to keep abreast of the latest research and developments, and to translate these into routine practice. Technological advances in diagnosis, surgical technique, new pharmaceuticals, molecular genetics and other basic sciences have transformed many aspects of how these diseases are managed. Such progress will accelerate.
Colorectal Disease offers a real benefit to subscribers and authors. It is first and foremost a vehicle for publishing original research relating to the demanding, rapidly expanding field of colorectal diseases.
Essential for surgeons, pathologists, oncologists, gastroenterologists and health professionals caring for patients with a disease of the lower GI tract, Colorectal Disease furthers education and inter-professional development by including regular review articles and discussions of current controversies.
Note that the journal does not usually accept paediatric surgical papers.